LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Amgen Inc

Geschlossen

BrancheGesundheitswesen

290.17 1.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

287.07

Max

292.94

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1B

1.7B

Verkäufe

-937M

8.1B

KGV

Branchendurchschnitt

26.32

51.198

EPS

4.9

Dividendenrendite

3.3

Gewinnspanne

21.23

Angestellte

28,000

EBITDA

-1.7B

1.2B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+13.61% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.30%

2.40%

Nächstes Ergebnis

5. Aug. 2025

Nächste Dividendenausschüttung

5. Sept. 2025

Nächstes Ex-Dividendendatum

15. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-3B

155B

Vorheriger Eröffnungskurs

289.04

Vorheriger Schlusskurs

290.17

Nachrichtenstimmung

By Acuity

39%

61%

126 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Amgen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2025, 20:17 UTC

Ergebnisse

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28. Mai 2025, 18:09 UTC

Ergebnisse

Heart Disease Could Be a Goner When These New -2-

28. Mai 2025, 18:09 UTC

Ergebnisse

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19. Mai 2025, 16:13 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen: FY25 Share Repurchases Not to Exceed $500M

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY25 Capital Expenditures About $2.3B

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Repatha Sales $656M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q EVENITY Sales $442M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Net $1.73B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Adj EPS $4.90 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q EPS $3.20 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Rev $8.15B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Rev $8.1B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Net $1.73B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen 1Q EPS $3.20 >AMGN

1. Mai 2025, 20:01 UTC

Ergebnisse

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Peer-Vergleich

Kursveränderung

Amgen Inc Prognose

Kursziel

By TipRanks

13.61% Vorteil

12-Monats-Prognose

Durchschnitt 326.18 USD  13.61%

Hoch 400 USD

Tief 252 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amgen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

21 ratings

10

Buy

10

Halten

1

Sell

Technischer Score

By Trading Central

270.44 / 276.44Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

126 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.